Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

3Q25 update

Challenger Financial Svcs
3:27pm
April 17, 2025
CGF has released its 3Q25 update. The key takeaway, in our view, was CGF has narrowed its FY25 NPAT guidance range to A$450m-A$465m (previously A$440m-A$480m), which indicates increased confidence with the current year outlook. We make relatively nominal changes to our CGF FY24F/FY25F EPS of ~-1%/-2%. Our PT rises to A$7.51, with our earnings changes offset by a valuation roll-forward. We think CGF has shown good earnings momentum in recent periods (3 year NPAT CAGR +11%), and with the stock trading on an undemanding ~11x FY25F PE multiple, we see further upside. ADD maintained.

1H25 earnings beat, FY26 ROE target offers upside

Bank of Queensland
3:27pm
April 16, 2025
1H25 EPS and DPS growth beat expectations. BOQ stands firm on its FY26 ROE and CTI targets, offering material upside to our upgraded forecasts and a potential valuation of >$10/sh if they are achieved. Our base case is more conservative, hence we retain a HOLD with 12 month potential TSR of c.8% at current prices. Upgraded cash EPS by 3%/6%/9% for FY25/26/27F, as we downgrade our NIM forecast, upgrade asset base growth (stronger loan growth), and reduce LIE (lower-for-longer). DCF valuation lifts 1% to $7.04/sh, as the earnings upgrade is offset by higher CET1 investment to meet the growth in RWA. Potential >$10/share valuation based on application of a P:BV vs ROE peer group regression.

Steel market pain helps Pilbara transition

Rio Tinto
3:27pm
April 16, 2025
As expected a softer start with a weather-impacted 1Q25 Pilbara performance. Copper was a bright spot coming in ahead as OTUG continues to shine. We continue to see RIO as trading below value while offering appealing relative safety in current dynamic market conditions. Maintain ADD rating, A$123 PT.

Highly leveraged to continued gold price strength

Evolution Mining
3:27pm
April 15, 2025
EVN delivered another strong production and cash flow result. Deleveraging continued at a rapid pace with net debt reducing 25% qoq and gearing now at ~19%. Strong cash flows give way to accelerated repayments of EVN’s term loans which will assist in an even more rapid deleveraging. We maintain our Hold rating with a A$8.00ps TP (previously A$5.90ps).

Partnership to bring Sports Direct Down Under

Accent Group
3:27pm
April 15, 2025
After much media speculation and following the initial strategic investment from UK retailer Frasers Group (FRAS.LSE) in August 2024, AX1 today announced it has made a long term agreement to roll out stores under Frasers’ flagship brand Sports Direct in Australia and New Zealand. The long term agreement will see AX1 rollout at least 50 stores over the next 6 years with an aspirational target of 100 stores in time. Frasers Group will increase its shareholding in AX1 to 19.57% (from 14.57%) via a placement of 35.2m shares at $1.718 per share (a 3.5% discount to Friday’s close). Proceeds from the placement ($60.4m) will be used to fund the initial roll-out of Sports Direct. AX1’s CEO, Daniel Agostinelli, has committed to remaining as CEO for at least another 3 years. We have lowered our EPS by 3% in FY25 and 2% in FY26. We have included a modest contribution for Sports Direct rollout into FY26/27. We have retained our HOLD recommendation, with a $2.00 price target, down from $2.20.

FDA approval- revolutionising heart failure treatment

EBR Systems
3:27pm
April 15, 2025
Despite what appears to be tumultuous time at US regulatory agencies, EBR delivered on its timeline and has received FDA’s blessing for its cardiac resynchronisation therapy (CRT) system (known as WiSE) for the treatment of heart failure, a major milestone after more than two decades in development. Encouragingly, contraindications are limited and the label aligns with the initially targeted cUS$3.6bn key market segments, including use with leadless pacemakers, with investor concern that Abbott’s Aveir was excluded, pending additional data, misplaced, in our view. We also believe the post-marketing study should not be viewed with any apprehension, as it is merely par for the course and in fact, should help strengthen the use case and label expansions over time. We continue to view commercial and manufacturing readiness, along with a reimbursement path that is both streamlined and incentivised, as helping to smooth the transition from developmental stage into a commercially viable medical device business. We make no changes to CY25-26 forecasts, and maintain our A$2.86 DCF-based valuation. With clinical risk now mitigated we move to an Add rating (from Speculative Buy).

1Q25 update

MA Financial Group
3:27pm
April 14, 2025
MAF has released its 1Q25 update. This showed that momentum is still generally reasonable across the MAF franchise in our view.  In summary, whilst Asset Management net flows were a bit below our expectations, MA Money lending growth was better than we expected. We downgrade our MAF FY25F/FY26F EPS by 4%-7% on lower Asset Management net inflows and AUM forecasts. Our PT is reduced to A$8.11 (previously A$8.92). We think MAF management are building a strong, differentiated franchise. We maintain our ADD recommendation, with significant upside existing to our price target.

Collateral damage

Reliance Worldwide
3:27pm
April 14, 2025
RWC’s share price has fallen 12% since the beginning of April and 23% over the past 3 months as uncertainty continues in relation to US tariffs on Chinese goods. US tariffs on Chinese goods (except certain consumer electronics) currently stands at 145%, although given recent history, this can turn on a dime and could depend on whether President Trump and President Xi can reach a deal. RWC predominantly manufactures key products in each region for sale within that region. However, cost of goods sold (COGS) for its Americas division includes ~US$120m in purchases from China that are subject to tariffs. We provide a scenario analysis on the impact on FY26F EBITDA for varying levels of US tariffs on Chinese goods against RWC’s ability to offset. Due to the highly uncertain outlook, we move our rating on RWC to Hold (from Add) as we await further clarity on tariffs and what this could mean for operating costs as well as revenue given risks to the global macroeconomic backdrop. We make no changes to EBITDA in FY25F but decrease both FY26F and FY27F by 7%. Our target price declines to $4.15 (from $5.80 previously).

Truly ground breaking moment

Imricor Medical Systems
3:27pm
April 13, 2025
The medical team at Amsterdam University Medical Centre have performed the first-in-human ventricular ablation guided by real time interventional cardiac magnetic resonance (iCMR) with IMR’s technology including its NorthStar mapping system. This has been a 20 year journey by IMR’s founder Steve Wedan and his team and marks a truly ground breaking moment in medical history. Following the recent A$70m capital raise, IMR is in a strong financial position to achieve a number of key catalysts including the approval of the NorthStar mapping system in Europe and US, secure approval in the US for atrial flutter, complete the Europe trail for ventricular tachycardia and drive sales in Europe and Middle East. We have made no changes to forecasts or our target price of A$2.28. IMR is a key pick in the emerging healthcare space and we maintain our speculative buy recommendation.

Strategic acquisitions make sense

Ebos Group
3:27pm
April 11, 2025
EBO is raising A$250m to help fund two strategic acquisitions; one in the NZ animal care market and the other completing full ownership of a SE Asian medical distributor. The acquisitions make sense and are being purchased on reasonable multiples. We have updated our model which results in a small valuation upgrade to A$39.15 (was A$38.56). Although the markets are uncertain we think EBO offers investors a company with a defensive earnings profile. We maintain an Add recommendation.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more